Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.
Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem.
1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'?.- Antipsychotic polypharmacy in USA.- Antipsychotic polypharmacy in Czech Republic and in Ukraine.- Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice.- Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational?.- Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice?.- Clozapine combinations in treatment-resistant schizophrenia patients.- Metabolic syndrome and antipsychotic polypharmacy.- Evidence based combination therapy for bipolar disorder.- Antidepressant combination strategies for major depressive disorder.- Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk.- Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy?.- Polypharmacy and potentially inappropriatemedication use among elders with dementia.- The role of polypharmacy in bipolar disorder treatment guidelines.
From the reviews: "The intent is to bring together a compendium of information from both clinical research and experience regarding the ever-increasing use of polypharmacy in the treatment of psychiatric conditions. ... should be read by anyone involved in the pharmacological management of psychiatric illnesses." (Michael Easton, Doody's Book Reviews, July, 2013)